Paul Harris, PhD
Dr. Harris is an Associate Professor of Medical Science (in Medicine) at Columbia University School of Medicine in Manhattan. He received his undergraduate degree from the University of California, Berkeley in Biochemistry and Medical Biophysics, his PhD in Cell Biology from Cornell University, and did Post Doctoral training in peptide chemistry at The Rockefeller University. He has been a faculty member at the health sciences campus of Columbia University since 1988. Dr Harris’ research efforts spanning 1990 to 2000 were instrumental in defining the structure of MHC bound peptides. Studies he co-authored provided the foundations for current vaccine design strategies.
Alessandro Sette, PhD
Dr. Alessandro Sette is the Head of the La Jolla Institute of Immunology (LJI) Division of Vaccine Discovery. Dr. Sette’s laboratory is focused on the study of the specific structures (epitopes) that the immune system recognizes, and uses this knowledge for a variety of applications including research relevant to vaccines for cancer therapy.
He created, and has directed since the early 2000s, the Immune Epitope Database, a freely available, widely used bioinformatics resource. Dr. Sette has devoted more than 30 years to understanding and measuring immune responses, and developing disease intervention strategies against cancer, autoimmunity, allergy, and infectious diseases. Dr. Sette has a doctorate in Biological Sciences from the University of Rome and was a postdoctoral fellow at the National Jewish Center in Denver, Colorado. In 1988, Dr. Sette joined Cytel Corp. and in 1997 founded Epimmune, where he was VP of Research and Chief Scientific Officer until 2002, when he joined LJI.
Nik Liolios
Nik is an AI data scientist and is a Product Manager at Google in Manhattan. He was a co-founder of Tetra (sold to Atrium) and was featured in Forbes “30 under 30” in Enterprise Technology. Nik is a graduate of Phillips Exeter Academy and left Tufts to join Y-Combinator and found Tetra. He is helping Flow Pharma’s bioinformatics team.
Jill Dietz, MD, FACS
Jill Dietz is Director of Breast Center Operations at University Hospitals Cleveland Medical Center and Associate Professor of Surgery at Case Western Reserve University School of Medicine. Her areas of research have included infections after surgery, oncoplastic techniques and the role that genetic factors play in developing breast cancer. She is currently a member of the American Society of Breast Surgeons Board of Directors, is on the publications and corporate relations committee, and Society of Surgical Oncology (SSO) SCORE education committee. She is advising Flow Pharma’s efforts against breast cancer.
In Memoria: Tom Hodge, PhD
Dr Hodge, former director of immunogenetics at the Centers for Disease Control and Prevention, spent decades fighting diseases such as AIDS and Ebola. He opted out of retirement in early 2020 to focus on the latest global public health threat and co-founded the CrisiScience Collaborative. He became a value member of Flow Pharma advisory team, a position that he served in for over two years. He died Saturday, July 31st, 2021 at St. Simons Island, Georgia. The team misses his sage advice and his down to earth humor.
Dr. Hodge received his PhD in Immunology from East Tennessee State University College of Medicine in 1982, subsequently spending over 15 years at at CDC serving from 1993-2005 as Director of the Immunogenetics Laboratory, Division of HIV/AIDS Pathogenesis National Center HIV, STD and TB Laboratory Research. Prior to that he served from 1989-1993 as Section Chief, Molecular Immunology, Immunology Branch, Division of HIV/AIDS Pathogenesis, National Center for Infectious Diseases, Centers for Disease Control and Prevention. Dr. Hodge had over 97 peer reviewed publications, in addition to book chapters, patents, and US IND applications.